{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:25:08Z","timestamp":1790490308600,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T cell therapy has made tremendous strides in the arena of hematological malignancies with approved therapies in certain leukemias, lymphomas, and recently myeloma with overall highly favorable response rates. While numerous clinical studies are still ongoing for hematological malignancies, research is developing to translate the feasibility of CAR T therapy in solid organ malignancies. Unfortunately, the majority of diagnosed cancers are primarily solid tumors. Thus, a highly unmet clinical need for further research and development exists in this field. This review article highlights currently active clinical trials and a few pertinent preclinical studies involving CAR T\u00a0cell therapy in solid tumors while briefly discussing study outcomes and potential key targets that may allow for the feasibility of this therapy option. Finally, we mention critical challenges existing in the solid tumor environment and discuss developing strategies that may potentially overcome the existing barriers to CAR T\u00a0cell progress in solid tumors.<\/jats:p>","DOI":"10.1002\/jha2.356","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T03:52:02Z","timestamp":1638935522000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["CAR T cell therapy in solid tumors: A review of current clinical trials"],"prefix":"10.1002","volume":"3","author":[{"given":"Urvi","family":"Patel","sequence":"first","affiliation":[{"name":"College of Pharmacy The University of Tennessee Health Science Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Abernathy","sequence":"additional","affiliation":[{"name":"College of Medicine The University of Tennessee Health Science Center  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N","family":"Savani","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010 Oncology Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010 Oncology Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010 Oncology Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010 Oncology Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.030"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy131"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21586"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou045"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2017.07.003"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0890"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1843628"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1421"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001097"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.74"},{"issue":"12","key":"e_1_2_13_17_1","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani P","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.014"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02166"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2163"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-00259-4"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23214"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00488-8"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1498845"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0189"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin\u2010targeted CAR T\u00a0cells: Safety and efficacy","volume":"79","author":"Adusumilli PS","year":"2019","journal-title":"Cancer Research"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3852"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12741"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17175-8"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2015.11.003"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.14405"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19361"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.008"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0224"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.030"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:12:00Z","timestamp":1693203120000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":45,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/jha2.356"],"URL":"https:\/\/doi.org\/10.1002\/jha2.356","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"2021-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}